Study design (if review, criteria of inclusion for studies)
RCT, crossover design with a 9-day washout.
Participants
8 adults with CF
Interventions
patients were randomized to receive intravenous (i.v.) and oral linezolid at 600 mg twice daily for 9 doses in a crossover design with a 9-day washout.
Outcome measures
Plasma samples were collected after the first and ninth doses of each phase. Population pharmacokinetic analyses were performed by nonlinear mixed-effects modeling using a previously described 2-compartment model with time-dependent clearance inhibition. Monte Carlo simulation was performed to assess the activities of the linezolid dosing regimens against 42 contemporary MRSA isolates recovered from CF patients.
Main results
A isolates; however, more frequent dosing may be required for isolates with MICs of ⥠2 μg/ml.